Updated on 28 September 2015
Jardiance has demonstrated positive result in reducing cardiovascular risk in patients with type 2 diabetes
Singapore: Jardiance, a diabetes drug by Boehringer Ingelheim and Eli Lilly, has demonstrated positive result in reducing cardiovascular risk and cardiovascular death in patients with type 2 diabetes (T2D).
EMPA-REG OUTCOME was a long-term, multicentre, randomised, double-blind, placebo-controlled trial that involved around 7,000 patients from 42 countries with type 2 diabetes at high risk for cardiovascular events. The study was designed to assess the effect of Jardiance (10mg or 25mg once daily) added to standard of care compared with placebo added to standard of care.
"People with Type 2 diabetes are at risk for cardiovascular diseases (stroke and heart attacks) not just from high blood sugar, but also other risk factors like high blood pressure, cholesterol, overweight and smoking," said Dr Kevin Tan, vice president, Diabetic Society of Singapore. "The EMPA-REG OUTCOME trial now provides physicians and patients with a treatment option that delivers on both blood glucose lowering as well as cardiovascular benefits. I am excited by the EMPA-REG OUTCOME results as they prove that newer therapies can be safe and beneficial for our Type 2 diabetes patients in Singapore."
Life expectancy of people with T2D at high CV risk is, on average, decreased by up to twelve years with approximately 50 percent of deaths in people with T2D caused by CV disease.
"The EMPA-REG OUTCOME trial results are encouraging for healthcare professionals and their patients," said Dr Christopher P Cannon, Cardiovascular Division, Brigham and Women's Hospital and Professor of Medicine, Harvard Medical School, who was not involved in the study. "Patients in the study were already being treated with medications that have been proven to reduce cardiovascular events. The observation that empagliflozin provided additional cardiovascular death reduction on top of these other medications is a very important finding."